Rapid COJEC versus standard induction therapies for high-risk neuroblastoma-Reference-Cited by-同舟云学术

Rapid COJEC versus standard induction therapies for high-risk neuroblastoma

Published:2015-05-19 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Peinemann Frank¹,Kahangire Doreen A²,van Dalen Elvira C³,Berthold Frank⁴

Affiliation:

1. University of Cologne; Children's Hospital; Kerpener Str. 62 Cologne NW Germany 50937

2. University of Birmingham; Birmingham and Black Country NIHR CLAHRC; School of Health and population, Public Health Building College of Medical and Dental Sciences Birmingham West Midlands UK B15 2TT

3. Emma Children's Hospital/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 (room H4-139) Amsterdam Netherlands 1100 DD

4. Children's Hospital, University of Cologne; Pediatric Oncology and Hematology; Kerpener Strasse 62 Cologne Germany 50937

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD010774.pub2/fullpdf

Reference65 articles.

1. Moreno L Vaidya S Pinkerton R Lewis IJ Imeson J Ellershaw C Abstract PL36. Long-term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden Stockholm Advances in Neuroblastoma Research Association (ANRA) 2010 105

2. Moreno L Vaidya S Pinkerton R Lewis IJ Imeson J Ellershaw C Abstract SEL10. Persistence of disease in long-term survivors of high-risk neuroblastoma. Analysis of ENSG5 cooperative trial The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden Stockholm Advances in Neuroblastoma Research Association (ANRA) 2010 136

3. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience;Moreno;Pediatric Blood and Cancer,2013

4. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial;Pearson;Lancet Oncology,2008

5. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival;Bomken;Pediatric Hematology and Oncology,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the myeloid microenvironment in neuroblastoma;Journal of Experimental & Clinical Cancer Research;2023-12-13

2. Neuroblastoma Interaction with the Tumour Microenvironment and Its Implications for Treatment and Disease Progression;Current Oncology;2023-10-15

3. Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma;Scientific Reports;2023-07-21

4. Neuroblastoma chemoimmunotherapy: current results and application prospects;Russian Journal of Pediatric Hematology and Oncology;2023-07-19

5. Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy;OncoImmunology;2023-03